|[June 11, 2014]
Genkyotex Appoints Daniel Elger as Chief Financial and Corporate Development Officer
GENEVA & ARCHAMPS, France --(Business Wire)--
Genkyotex, the leading developer of selective NOX enzyme inhibitors,
announced today the appointment of Dr. Daniel Elger as Chief Financial
and Corporate Development Officer. He joins Genkyotex with more than 15
years biotech and pharmaceutical industry experience.
"Daniel's extensive strategic expertise, including experience in
fundraising and the public markets, is a great asset to the Genkyotex
team," stated Dr. Ursula Ney, Chief Executive Officer. "As Genkyotex
grows and we advance our clinical pipeline, Daniel will play a key role
in further developing our corporate strategy to leverage our world
leading position in developing this new drug class of NOX inhibitors."
Dr. Elger was most recently Chief Financial Officer and a Board Director
of e-Therapeutics plc, a London Stock Exchange (LSE) AIM-listed drug
discovery and development company, where he played a central role in a
substantial fundraising. Prior to that role, he was Vice President,
Marketing and Communications, at LSE-listed oncology comany Antisoma
plc, where he served on the Senior Management Team and had significant
roles in corporate strategy, fundraisings and the acquisition of two US
biotech companies, as well as directing the company's investor relations
and communications programmes. Earlier in his career, Dr. Elger worked
in marketing and communications agencies serving major pharma companies.
He holds a BA in Physiological Sciences (Medicine) and a PhD in cancer
cell biology, both from Oxford University.
Genkyotex is developing first in class, small molecule therapeutics that
specifically and selectively inhibit the NOX family of enzymes. Using a
unique screening platform, Genkyotex has identified novel NOX inhibitors
with the potential to treat disease areas with a high clinical need and
large market potential. The company's lead product, GKT137831, is now in
a Phase 2 clinical study in patients with diabetic nephropathy and has
shown promise in several other disease models, including
atherosclerosis, lung and liver fibrosis, osteoporosis, and in models of
angiogenesis. Genkyotex was founded in 2006 by scientists from
Switzerland, the USA and Japan, with backing from Geneva incubator
Eclosion. Since 2011, expansion of the investor base, led by Edmond de
Rothschild Investment Partners, with Vesalius BioCapital and MP
Healthcare Venture Management, has provided significant investment to
Genkyotex. Further information can be found at: www.genkyotex.com.
[ Back To TMCnet.com's Homepage ]